With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

We recently compiled a list of the 11 Best Undervalued Stocks ... It is well-known for its treatments like EPOGEN, Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst ...

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research ... Aranesp and Neulasta. Meanwhile, the acquisition ...

Using the screener we aggregated a list of stocks trading below the forward ... It is well-known for its treatments like EPOGEN, Aranesp, Neulasta, and Repatha, among others.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

The company plans to list its key Biosimilar business by March ... novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Check out More Related Studies Published by Fact: The oncology biosimilars market is set to grow from $4.2 billion in 2022 to $12 billion by 2032, with an 11% CAGR. The pegfilgrastim biosimilar ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...